Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Treatment response prediction and individualized identification of first-episode drug-naïve schizophrenia using brain functional connectivity


Identifying biomarkers in schizophrenia during the first episode without the confounding effects of treatment has been challenging. Leveraging these biomarkers to establish diagnosis and make individualized predictions of future treatment responses to antipsychotics would be of great value, but there has been limited progress. In this study, by using machine learning algorithms and the functional connections of the superior temporal cortex, we successfully identified the first-episode drug-naive (FEDN) schizophrenia patients (accuracy 78.6%) and predict their responses to antipsychotic treatment (accuracy 82.5%) at an individual level. The functional connections (FC) were derived using the mutual information and the correlations, between the blood-oxygen-level dependent signals of the superior temporal cortex and other cortical regions acquired with the resting-state functional magnetic resonance imaging. We also found that the mutual information and correlation FC was informative in identifying individual FEDN schizophrenia and prediction of treatment response, respectively. The methods and findings in this paper could provide a critical step toward individualized identification and treatment response prediction in first-episode drug-naive schizophrenia, which could complement other biomarkers in the development of precision medicine approaches for this severe mental disorder.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type



Prices may be subject to local taxes which are calculated during checkout

Fig. 1


  1. Whiteford HA, Degenhardt L, Rehm J, Baxter AJ, Ferrari AJ, Erskine HE, et al. Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. Lancet. 2013;382:1575–86.

    PubMed  Google Scholar 

  2. Fraguas D, Diaz-Caneja CM, Pina-Camacho L, Janssen J, Arango C. Progressive brain changes in children and adolescents with early-onset psychosis: a meta-analysis of longitudinal MRI studies. Schizophr Res. 2016;173:132–9.

    PubMed  Google Scholar 

  3. Moylan S, Maes M, Wray NR, Berk M. The neuroprogressive nature of major depressive disorder: pathways to disease evolution and resistance, and therapeutic implications. Mol Psychiatry. 2012;18:595–606.

    PubMed  Google Scholar 

  4. Berk M, Conus P, Lucas N, Hallam K, Malhi GS, Dodd S, et al. Setting the stage: from prodrome to treatment resistance in bipolar disorder. Bipolar Disord. 2007;9:671–8.

    PubMed  Google Scholar 

  5. Passos IC, Mwangi B, Vieta E, Berk M, Kapczinski F. Areas of controversy in neuroprogression in bipolar disorder. Acta Psychiatr Scand. 2016;134:91–103.

    CAS  PubMed  Google Scholar 

  6. Cao B, Passos IC, Mwangi B, Amaral-Silva H, Tannous J, Wu M-J, et al. Hippocampal subfield volumes in mood disorders. Mol Psychiatry. 2017;22:1352–1358.

  7. Ho NF, Iglesias JE, Sum MY, Kuswanto CN, Sitoh YY, De Souza J, et al. Progression from selective to general involvement of hippocampal subfields in schizophrenia. Mol Psychiatry. 2017 Jan; 22(1): 142–152

  8. Vita A, De Peri L, Deste G, Sacchetti E. Progressive loss of cortical gray matter in schizophrenia: a meta-analysis and meta-regression of longitudinal MRI studies. Transl Psychiatry. 2012;2:e190.

    CAS  PubMed  PubMed Central  Google Scholar 

  9. Cloutier M, Sanon Aigbogun M, Guerin A, Nitulescu R, Ramanakumar AV, Kamat SA, et al. The economic burden of schizophrenia in the United States in 2013. J Clin Psychiatry. 2016;2012:764–71.

    Google Scholar 

  10. Schnack HG, Nieuwenhuis M, van Haren NEM, Abramovic L, Scheewe TW, Brouwer RM, et al. Can structural MRI aid in clinical classification? A machine learning study in two independent samples of patients with schizophrenia, bipolar disorder and healthy subjects. Neuroimage. 2014;84:299–306.

    PubMed  Google Scholar 

  11. Kambeitz J, Cabral C, Sacchet MD, Gotlib IH, Zahn R, Serpa MH, et al. Detecting neuroimaging biomarkers for depression: a meta-analysis of multivariate pattern recognition studies. Biol Psychiatry. 2016;40:1742–51.

    Google Scholar 

  12. Fusar-Poli P, Smieskova R, Kempton MJ, Ho BC, Andreasen NC, Borgwardt S. Progressive brain changes in schizophrenia related to antipsychotic treatment? A meta-analysis of longitudinal MRI studies. Neurosci Biobehav Rev. 2013;37:1680–91.

    CAS  PubMed  PubMed Central  Google Scholar 

  13. Baglivo V, Cao B, Mwangi B, Bellani M, Perlini C, Lasalvia A, et al. Hippocampal subfield volumes in patients with first-episode psychosis. Schizophrenia Bulletin. 2017;44:3, 6 April 552–559.

  14. Emsley RA. Risperidone in the treatment of first-episode psychotic patients: a double-blind multicenter study. Schizophr Bull. 1999;25:721–9.

    CAS  PubMed  Google Scholar 

  15. Johnsen E, Jørgensen HA. Effectiveness of second generation antipsychotics: a systematic review of randomized trials. BMC Psychiatry. 2008;8:31

    PubMed  PubMed Central  Google Scholar 

  16. Komossa K, Rummel-Kluge C, Schwarz S, Schmid F, Hunger H, Kissling W, et al. Risperidone versus other atypical antipsychotics for schizophrenia. In: Cochrane Database of Systematic Reviews. 2011

  17. Wang C, Shi W, Huang C, Zhu J, Huang W, Chen G. The efficacy, acceptability, and safety of five atypical antipsychotics in patients with first-episode drug-naïve schizophrenia: a randomized comparative trial. Ann Gen Psychiatry. 2017;16:47

    Article  PubMed  PubMed Central  Google Scholar 

  18. Emsley R, Rabinowitz J, Medori R. Time course for antipsychotic treatment response in first-episode schizophrenia. Am J Psychiatry. 2006;163:743–5.

    PubMed  Google Scholar 

  19. Rattehalli RD, Zhao S, Li BG, Jayaram MB, Xia J, Sampson S Risperidone versus placebo for schizophrenia. Cochrane Database Syst. Rev. 2016; 2016.

  20. Dale AM, Fischl B, Sereno MI. Cortical surface-based analysis. I. Segmentation and surface reconstruction. Neuroimage. 1999;9:179–94.

    CAS  PubMed  Google Scholar 

  21. Jovicich J, Czanner S, Greve D, Haley E, Van Der Kouwe A, Gollub R, et al. Reliability in multi-site structural MRI studies: effects of gradient non-linearity correction on phantom and human data. Neuroimage. 2006;30:436–43.

    PubMed  Google Scholar 

  22. Fischl B, Salat DH, Busa E, Albert M, Dieterich M, Haselgrove C, et al. Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron. 2002;33:341–55.

    CAS  PubMed  Google Scholar 

  23. Desikan RS, Ségonne F, Fischl B, Quinn BT, Dickerson BC, Blacker D, et al. An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage. 2006;31:968–80.

    PubMed  Google Scholar 

  24. Zhou D, Thompson WK, Siegle G. MATLAB toolbox for functional connectivity. Neuroimage. 2009;47:1590–607.

    PubMed  PubMed Central  Google Scholar 

  25. Salvador R, Suckling J, Schwarzbauer C, Bullmore E. Undirected graphs of frequency-dependent functional connectivity in whole brain networks. Philos Trans R Soc B Biol Sci. 2005;360:937–46.

    Google Scholar 

  26. Nichols T, Hayasaka S. Controlling the familywise error rate in functional neuroimaging: a comparative review. Stat Methods Med Res. 2003;12:419–46.

    PubMed  Google Scholar 

  27. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B 1995;57:289–300.

    Google Scholar 

  28. Pedregosa F, Varoquaux G Scikit-learn: Machine learning in Python. 2011

  29. Cao B, Luo Q, Fu Y, Du L, Qiu T, Yang X, et al. Predicting individual responses to the electroconvulsive therapy with hippocampal subfield volumes in major depression disorder. Sci Rep. 2018;8:5434.

    PubMed  PubMed Central  Google Scholar 

  30. Cortes C, Vapnik V. Support-vector networks. Machine Learning. 1995;20(3):273–297.

  31. Kay SR, Opler LA, Fiszbein A. Positive and Negative Syndrome Scale Rating Criteria. 1999.

  32. Arbabshirani MR, Kiehl KA, Pearlson GD, Calhoun VD. Classification of schizophrenia patients based on resting-state functional network connectivity. Front Neurosci. 2013;7:1–16.

    Google Scholar 

  33. Davatzikos C, Shen D, Gur RCRE, Wu X, Liu D, Fan Y, et al. Whole-brain morphometric study of schizophrenia revealing a spatially complex set of focal abnormalities. Arch Gen Psychiatry. 2005;62:1218–27.

    PubMed  Google Scholar 

  34. Sun D, van Erp TGM, Thompson PM, Bearden CE, Daley M, Kushan L, et al. Elucidating a magnetic resonance imaging-based neuroanatomic biomarker for psychosis: classification analysis using probabilistic brain atlas and machine learning algorithms. Biol Psychiatry. 2009;66:1055–60.

    PubMed  PubMed Central  Google Scholar 

  35. Gheiratmand M, Rish I, Cecchi GA, Brown MRG, Greiner R, Polosecki PI, et al. Learning stable and predictive network-based patterns of schizophrenia and its clinical symptoms. npj Schizophr. 2017;3:22.

    PubMed  PubMed Central  Google Scholar 

  36. Borgwardt S, Koutsouleris N, Aston J, Studerus E, Smieskova R, Riecher-Rössler A, et al. Distinguishing prodromal from first-episode psychosis using neuroanatomical single-subject pattern recognition. Schizophr Bull. 2013;39:1105–14.

    PubMed  Google Scholar 

  37. Liu Y, Teverovskiy L, Carmichael O, Kikinis R, Shenton M, Carter CS, et al. Discriminative MR image feature analysis for automatic schizophrenia and Alzheimer’s disease classification. In: MICCAI. Medical Image Computing and Computer-Assisted Intervention – MICCAI 2004, 393–401.

  38. Mourao-Miranda J, Reinders AATS, Rocha-Rego V, Lappin J, Rondina J, Morgan C, et al. Individualized prediction of illness course at the first psychotic episode: a support vector machine MRI study. Psychol Med. 2012;42:1037–47.

    CAS  PubMed  Google Scholar 

  39. Rathi Y, Malcolm J, Michailovich O, Goldstein J, Seidman L, McCarley RW, et al. Biomarkers for identifying first-episode schizophrenia patients using diffusion weighted imaging. Med image Comput Comput Interv Part 1 2010: 657–65.

  40. Schwarz D, Kasparek T. Brain morphometry of MR images for automated classification of first-episode schizophrenia. Inf Fusion. 2014;19:97–102.

    Google Scholar 

  41. Pettersson-Yeo W, Benetti S, Marquand AF, Dell’acqua F, Williams SCR, Allen P, et al. Using genetic, cognitive and multi-modal neuroimaging data to identify ultra-high-risk and first-episode psychosis at the individual level. Psychol Med. 2013;43:2547–62.

    CAS  PubMed  PubMed Central  Google Scholar 

  42. Ramyead A, Studerus E, Kometer M, Uttinger M, Gschwandtner U, Fuhr P, et al. Prediction of psychosis using neural oscillations and machine learning in neuroleptic-naive at-risk patients. World J Biol Psychiatry. 2015;2975:1–11.

    Google Scholar 

  43. Chua SE, Cheung C, Cheung V, Tsang JTK, Chen EYH, Wong JCH, et al. Cerebral grey, white matter and csf in never-medicated, first-episode schizophrenia. Schizophr Res. 2007;89:12–21.

    PubMed  Google Scholar 

  44. Pietersen CY, Mauney Sa, Kim SS, Passeri E, Lim MP, Rooney RJ, et al. Molecular profiles of parvalbumin-immunoreactive neurons in the superior temporal cortex in schizophrenia. J Neurogenet. 2014;28:1–16.

    Google Scholar 

  45. Mueller TM, Yates SD, Haroutunian V, Meador-Woodruff JH. Altered fucosyltransferase expression in the superior temporal gyrus of elderly patients with schizophrenia. Schizophr Res. 2017;182:66–73.

    PubMed  Google Scholar 

  46. Steiner J, Brisch R, Schiltz K, Dobrowolny H, Mawrin C, Krzyzanowska M, et al. GABAergic system impairment in the hippocampus and superior temporal gyrus of patients with paranoid schizophrenia: a post-mortem study. Schizophr Res. 2016;177:10–17.

    PubMed  Google Scholar 

  47. Guo W, Xiao C, Liu G, Wooderson SC, Zhang Z, Zhang J, et al. Decreased resting-state interhemispheric coordination in first-episode, drug-naive paranoid schizophrenia. Prog Neuro-Psychopharmacol Biol Psychiatry. 2014;48:14–19.

    Google Scholar 

  48. McKinney B, Ding Y, Lewis DA, Sweet RA. DNA methylation as a putative mechanism for reduced dendritic spine density in the superior temporal gyrus of subjects with schizophrenia. Transl Psychiatry. 2017;7:e1032.

    CAS  PubMed  PubMed Central  Google Scholar 

  49. Lui S, Deng W, Huang X, Jiang L, Ma X, Chen H, et al. Association of cerebral deficits with clinical symptoms in antipsychotic-naive first-episode schizophrenia: An optimized voxel-based morphometry and resting state functional connectivity study. Am J Psychiatry. 2009;166:196–205.

    PubMed  Google Scholar 

  50. Straube B, Green A, Sass K, Kircher T. Superior temporal sulcus disconnectivity during processing of metaphoric gestures in Schizophrenia. Schizophr Bull. 2014;40:936–44.

    PubMed  Google Scholar 

  51. Shah C, Zhang W, Xiao Y, Yao L, Zhao Y, Gao X, et al. Common pattern of gray-matter abnormalities in drug-naive and medicated first-episode schizophrenia: a multimodal meta-analysis. Psychol Med. 2017;47:401–13.

    CAS  PubMed  Google Scholar 

  52. Barta PE, Pearlson GD, Powers RE, Richards SS, Tune LE. Auditory hallucinations and smaller superior temporal gyrus volume in schizophrenia. Am J Psychiatry. 1990;147:604–12.

    Google Scholar 

  53. Friston KJ. The disconnection hypothesis. Schizophrenia Research 1998;30:115–25.

  54. Sarpal DK, Robinson DG, Lencz T, Argyelan M, Ikuta T, Karlsgodt K, et al. Antipsychotic treatment and functional connectivity of the striatum in first-episode schizophrenia. JAMA Psychiatry. 2015;72:5–13.

    PubMed  PubMed Central  Google Scholar 

  55. Sarpal DK, Argyelan M, Robinson DG, Szeszko PR, Karlsgodt KH, John M, et al. Baseline striatal functional connectivity as a predictor of response to antipsychotic drug treatment. Am J Psychiatry. 2016;173:69–77.

    PubMed  Google Scholar 

  56. Lally J, MacCabe JH. Antipsychotic medication in schizophrenia: a review. Br Med Bull. 2015;114:169–79.

    CAS  PubMed  Google Scholar 

Download references


Supported in part by the NARSAD Young Investigator Grant of the Brain & Behavior Research Foundation (B.C.), the Michael E. Debakey VA Medical Center and the Beth K. and Stuart C. Yudofsky Division of Neuropsychiatry, Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine in Houston, TX (R.Y.C.), and NIMH grant R01 085667, the Dunn Research Foundation and the Pat Rutherford, Jr. Endowed Chair in Psychiatry (J.C.S.).

Author information

Authors and Affiliations


Corresponding author

Correspondence to Xiang Yang Zhang.

Ethics declarations

Conflict of interest

B.C., R.Y.C., D.C., M.X., L.W., and X.Y.Z. reported no biomedical financial interests or potential conflicts of interest. J.C.S. has received grants/research support from Forrest, BMS, J&J, Merck, Stanley Medical Research Institute, NIH and has been a speaker for Pfizer and Abbott.

Electronic supplementary material

Rights and permissions

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cao, B., Cho, R.Y., Chen, D. et al. Treatment response prediction and individualized identification of first-episode drug-naïve schizophrenia using brain functional connectivity. Mol Psychiatry 25, 906–913 (2020).

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:


  • support vector machines
  • SVM

This article is cited by


Quick links